Coherus Oncology (CHRS) Other financing activities (2014 - 2026)

Coherus Oncology has disclosed Other financing activities across 12 years of filings, most recently posting $52000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $52000.0, down 80.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $93000.0 (down 95.31% YoY), and the FY2025 annual result was -$832000.0, down 2034.88% from the prior year.
• Other financing activities came in at $52000.0 for Q1 2026 at Coherus Oncology, up from $22000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $2.8 million in Q1 2023 to a low of -$367000.0 in Q4 2022.
• The 5-year median for Other financing activities is $189500.0 (2023), against an average of $567437.5.
• Across the five-year window, Other financing activities slumped 116.35% in 2022 and soared 460.98% in 2024, its largest moves.
• Coherus Oncology's Other financing activities stood at -$367000.0 in 2022, then surged by 45.78% to -$199000.0 in 2023, then surged by 105.03% to $10000.0 in 2024, then surged by 120.0% to $22000.0 in 2025, then soared by 136.36% to $52000.0 in 2026.
• The last three Other financing activities figures came in at $52000.0 (Q1 2026), $22000.0 (Q4 2025), and $3000.0 (Q3 2025), per Business Quant data.